Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Blog | November 01, 2022

ITC Monthly Wrap-Up: October 2022

Blog | November 01, 2022

Limelight v. Akamai: A software case worthy of biotech's attention

Article | October 20, 2022

Life Sciences Entrepreneur Sourcebook | Intellectual Property: What It Is and Why You Should Care

Article | October 12, 2022

Five Tips to Create a Battle-Ready Portfolio From the Get-Go

Blog | October 11, 2022

Federal Circuit Affirms PTAB's Final Written Decision that Merck's Claimed Inventions Were Not "At Once Envisaged" From the Prior Art

Blog | October 11, 2022

Legal Alert: Unitary Patent and UPC Start Date Target Is Now 1 April 2023

Blog | October 05, 2022

DDE Excludes Damages Testimony Based on "Built-In Apportionment," Prior Jury Verdicts, and Settlement Agreements

Blog | October 05, 2022

ITC Monthly Wrap-Up: September 2022

Blog | October 04, 2022

Texas Patent Litigation Monthly Wrap-Up: September 2022

Article | September 29, 2022

Congress and the America Invents Act — An Update on Recent Developments in the Senate

Article | September 20, 2022

2022 Ushers in New Developments in the Patent Review Process

Blog | September 15, 2022

What to Know About the USPTO's Duty of Candor Guidance Regarding FDA Submissions